Stockscreener 앱 받기
0.8556
1.50%
-0.013
시간 외 거래:
.88
0.0244
+2.85%
Biofrontera Inc 주식(BFRI)의 최신 뉴스
Biofrontera Earnings Call: Profits Rise, Risks Remain - TipRanks
BFRIW SEC FilingsBiofrontera 10-K, 10-Q, 8-K Forms - Stock Titan
BIOFRONTERA ($BFRI) Releases Q4 2025 Earnings - Quiver Quantitative
Biofrontera reports rise in Q4 revenue, turns profitable - MSN
[10-K] Biofrontera Inc. Files Annual Report | BFRI SEC FilingForm 10-K - Stock Titan
Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition - MSN
Biofrontera Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biofrontera 2025 Financial Results: Record Annual & Quarterly RevenueNews and Statistics - IndexBox
Biofrontera Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Biofrontera (BFRI) Q4 2025 Financial Results Transcript - Bitget
Biofrontera (BFRI) Q4 2025 Earnings Transcript - The Globe and Mail
BFRI: Record revenue, improved margins, and clinical progress set up strong 2026 growth - TradingView
Earnings call transcript: Biofrontera Inc. Q4 2025 sees record revenue growth - Investing.com UK
Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year - TipRanks
Biofrontera reports record Q4 revenue $17.1M, Q4 gross margin 82.4% and Q4 net income $5.6M - TradingView
Record Q4 for Biofrontera (NASDAQ: BFRI) with 36% revenue growth - Stock Titan
Biofrontera turns Q4 profitable after cutting Ameluz earnout payments - Stock Titan
Price Action: Does Biofrontera Inc have a sustainable dividend2026 Pullbacks & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Nasdaq Moves: Does Biofrontera Inc Equity Warrant have pricing power2026 Snapshot & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Biofrontera Inc expected to post earnings of 20 cents a shareEarnings Preview - TradingView
BFRIWBiofrontera Latest Stock News & Market Updates - Stock Titan
Analysts Offer Insights on Healthcare Companies: OS Therapies Incorporated (OSTX), Legend Biotech (LEGN) and Biofrontera (BFRI) - The Globe and Mail
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Are healthcare shares trailing behind Align Technology (ALGN) in performance this year? - Bitget
PTA-Adhoc: Biofrontera AG: Financial Guidance for FY 2026 - TradingView
Market Rankings: Is Biofrontera Inc backed by strong institutional buying2026 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Bitget
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - The Manila Times
Biofrontera Inc. to Report Fourth Quarter and Full Year - GlobeNewswire
Biofrontera reports Phase 2b acne trial results for Ameluz PDT - Investing.com India
Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - The Manila Times
Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView
Biofrontera Inc. Reports Positive Phase 2b Results - GlobeNewswire
Is Biofrontera Inc. backed by strong institutional buyingQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Loss Report: Does Biofrontera Inc have a sustainable dividendDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Biofrontera Inc. (BFRI) CFO granted RSUs, options and stock conversion - Stock Titan
Biofrontera grants RSUs and options to executive | BFRI SEC FilingForm 4 - Stock Titan
BFRIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Biofrontera Inc. stock go up in YEAR2025 Top Gainers & Risk Controlled Stock Alerts - mfd.ru
Bank Watch: Is Biofrontera Inc a play on infrastructure spendingJuly 2025 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn
Biofrontera wins patent ruling against Sun Pharma in dispute By Investing.com - Investing.com Canada
Biofrontera wins patent ruling against Sun Pharma in dispute - Investing.com
Biofrontera reports USPTO decision on Sun Pharma’s challenged claims - TipRanks
Biofrontera Wins Key PTAB Ruling in Sun Patent Dispute - TipRanks
Biofrontera (NASDAQ: BFRI) wins PTAB decision on Sun Pharma patent claims - Stock Titan
U.S. Patent Office Issues Final Written Decision Finding - GlobeNewswire
Gains Recap: Will Biofrontera Inc stock go up in YEAR2025 Trading Recap & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Is Biofrontera Inc. stock technically oversoldWeekly Stock Analysis & Community Consensus Trade Signals - mfd.ru
Growth Value: Can Biofrontera Inc Equity Warrant sustain its profitabilityLong Setup & Weekly Breakout Watchlists - baoquankhu1.vn
BFRIBiofrontera Inc Latest Stock News & Market Updates - Stock Titan
Trading Action: Does Biofrontera Inc have high return on assets2025 Risk Factors & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Can Biofrontera Inc Equity Warrant sustain its profitabilityMarket Growth Report & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
How Biofrontera Inc. Equity Warrant stock responds to policy changesJuly 2025 Retail & Low Drawdown Momentum Ideas - mfd.ru
Fundamentals Check: Can Biofrontera Inc Equity Warrant navigate macro headwindsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Biofrontera completes key study for Ameluz skin treatment expansion By Investing.com - Investing.com South Africa
Biofrontera Emerges as Stronger Biotech Stock Compared to RenovaCare - National Today
Biofrontera completes key study for Ameluz skin treatment expansion - Investing.com
Biofrontera Inc (NASDAQ: BFRI) recently announced that the database lock for its Phase I pharmacokinetic study of Ameluz® for actinic keratosis on the trunk and extremities has been completed. - Bitget
Biofrontera Inc. Announces Database Lock of Phase 1 - GlobeNewswire
Travel Stocks: Does Biofrontera Inc have a sustainable dividend2025 Biggest Moves & High Return Trade Opportunity Guides - baoquankhu1.vn
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - The Manila Times
Biofrontera reports positive phase 3 data for Ameluz in actinic keratosis - MSN
Bull Run: Is now the right time to enter Biofrontera Inc Equity Warrant - baoquankhu1.vn
BFRI SEC FilingsBiofrontera Inc 10-K, 10-Q, 8-K Forms - Stock Titan
2.02%
0.77%
자본화:
|
볼륨(24시간):